Ten Carbon Chemistry

MARCH 2023



TEN CARBON CHEMISTRY

OUR STORY

Mission

To provide safe, effective, and sustainable antimicrobial solutions to global markets to support food safety, maintain recycling, and protect public health.

2020

Started at Wintermute biomedical, an **antimicrobial therapeutics company**.

COVID **created urgent need for environmental antimicrobials**: hand sanitisers & surface disinfectants.

Realisation that the antimicrobial technology could be used more broadly than just medical uses.

Wintermute began making and testing **commercial sanitisers**.

2021

Expanded beyond cleaning and hygiene to testing in meat processing facilities and glass recycling.

Refined our model and focus, getting feedback from markets and customers.

2022

Ten Carbon Chemistry was created to focus on repurposing the technology for **non-medical applications**.

Split off timing to capitalise on our momentum and focus on growing revenue.

INDUSTRIAL, ENVIRONMENTAL, AND AGRICULTURAL ANTIMICROBIALS

Widely used non-medical uses of antimicrobials.



WHERE THEY'RE USED

Environment & Industry, Agriculture, Cleaning & Hygiene



WHAT THEY'RE USED FOR

- Reduce contamination of bacteria, fungi, and viruses
 - Prevent disease spread in humans and livestock
 - Prevent food spoilage
 - Control smell



WHAT THEY CONTAIN (OUR COMPETITORS)

- Quaternary ammonium compounds (quats)
- Alcohol
- Bleach
- Formaldehyde

PROBLEM WITH EXISTING ANTIMICROBIALS

Limitations of competitor products.

INCREASING ANTIBIOTIC RESISTANCE

- Reducing the effectiveness of current antimicrobials
- Caused by antimicrobial overuse
- >1.2 million people died in 2019 as a direct result of antibiotic resistance

2

MANY ARE DANGEROUS

Health and OHS concerns
e.g. quats, formaldehyde

Two hygiene giants - **The Clorox Company & Reckitt** have acknowledged these concerns by advertising that they are seeking alternatives.

OUR SOLUTION

An antimicrobial platform with robust activity, safety, and flexibility.



Core formulation verified

by independent laboratories and universities.

Worldwide license from parent company

- For all nonmedical uses, & medical uses for livestock
- Exclusive 20-year license
- Royalty-free period

BENEFITS OF OUR SOLUTION

Our formulations provide a competitive advantage over current offerings.

Benefits to Customers



Superior activity to current antimicrobials Reduces profit loss from unusable product. Provides a long-term effective solution.

Benefits to Public Health



Reduces biosecurity threat e.g. Foot and mouth disease, avian flu



Long-lasting activity Antimicrobial activity remains on surfaces, so fewer applications needed.



Reduces spread of disease e.g. Food poisoning



Safe for workers and livestock

Free of harmful ingredients such as quats and ammonia and OHS benefits.



Reduces threat of antimicrobial resistance Ensures medical antibiotics remain effective.

A MULTIPLE MARKET OPPORTUNITY

Wide variety of use-cases.



MONETISATION

BUSINESS MODEL

We co-design solutions with end users for seamless market fit and rapid adoption.

Stage 2

Stage 1 **Partner with industry leaders** seeking better antimicrobials: Suppliers and end consumers with a clear need for a new solution.

Tailor solution: Co-design and tailor antimicrobial solutions with partners; ensure market offering is in line with customer needs and use case.

Stage 3 Validation and testing: Trial product at partner sites and in lab testing; joint access to scientific methodology and results.

Stage 4 Sales or sub-license for selected use: Long-term contracts with buyers; license to suppliers allows existing suppliers to sell to the market

through their established pipelines.

PARTNER WITH INDUSTRY LEADERS	DISCUSS MARKET NEEDS	TRIAL ON SITE	SALES
	IDENTIFY PAIN POINTS	LAB TESTING	
	IDENTIFY REGULATORY REQUIREMENTS	OBTAIN REGULATORY APPROVAL	LICENSE
	γ		License fees at 2–8%

MONETISATION

GROWTH STRATEGY

Growing sales and sub-licenses and expanding to new sites and regions whilst continuing to build specialised use cases to enter new markets for rapid business expansion.



MOMENTUM

TRACTION

Awards, accelerators, credibility, and revenue.



IFPA Accelerator 1 of 12 companies selected



InClean Excellence Award Innovative Cleaning Agent category



\$350,000 Raised in Pre-Seed Round From parent-company investors



USDA Grant

\$260,000 USD over 2 years to test product on reusable food packaging



Revenue Generating Partner

Glass recycling; 2 plants out of 10 in Australia.



3 Peer-Reviewed Publications

Demonstrating efficacy in lab testing and superior activity on pork abattoir surfaces

MOMENTUM TESTIMONIAL



MOMENTUM

WHERE WE ARE NOW

Partnerships

15

Markets

Use Cases



NanoKill - On crushed glass to stop odour

- Re-selling to waste management sites
- Revenue generating in FY21-22
- 2 of 10 Australian sites secured



Sanitiser in meat processing facilities

 Preliminary testing complete, in discussion to increase sales

Sanitiser in livestock housing

 Engaging with partners to begin testing on site

Establishing

PLANT AGRICULTURE (pre-harvest)



On crops as an insecticide

 Co-filing patent for new use in March, sub-license to follow

On crops as a fungicide

• Testing beginning in Feb

Establishing



On food to prevent spoilage

 Preliminary testing at partner sites

On food packaging to prevent food spoilage

• Funded by USDA grant

3 YEAR ROADMAP - PROJECTED VALUE PROPOSITIONS

TARGET SALES MILESTONES



TARGET R&D MILESTONES

Further product development and refinement to provide greater consumer confidence, superior product differentiation, and entry into new markets.

All markets & uses			Specific markets & uses
Validate residual activity in different use cases	Understand resistance profile	Determine activity against biofilms	Establish new partners to enter new markets with new use cases:
			ON FRESH PRODUCE
RESIDUAL ACTIVITY	RESISTANCE PROFILE	BIOFILMS	IN ANIMAL BEDDING
			ON LIVESTOCK ANIMALS

Research subsidised with grant funding e.g. CRC-P Utilising the Australian R&D tax rebate **EXIT**

Potential for medium-term exit via a trade sale, with similar industry acquisitions recently completed.



MEET OUR TEAM

Our executive team has over 75 years of experience in science and commercialisation.



COMPANY HIGHLIGHTS



We welcome discussions about investment opportunities with us.

Dr Tony Peacock
+61 402 036 110
tony.peacock@tencarbon.com